**UNITED STATES   SECURITIES AND EXCHANGE COMMISSION  Washington, D.C. 20549**

**SCHEDULE 13D  Under the Securities Exchange Act of 1934   (Amendment No. 4)***

**MFIC Corporation**(Name of Issuer) 

Common Stock, par value $0.01 per share(Title of Class of Securities) 

**595073 10 7**(CUSIP Number) 

**Margaret M. Foran   Vice President - Corporate Governance and Secretary   Pfizer Inc. 235 East 42nd Street   New York, New York 10017   ( 212)-733-4802**(Name, Address and Telephone Number of Person Authorized to Receive  Notices and Communications) 

**December 31, 2004**(Date of Event which Requires Filing of this Statement) 

> 
Check the appropriate box to designate the rule pursuant to which this      Schedule is filed:

_ Rule 13d-1(b)

x Rule 13d-1(c)

_ Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's      initial filing on this form with respect to the subject class of securities,      and for any subsequent amendment containing information which would alter      the disclosures provided in a prior cover page. 

The information required on the remainder of this cover page shall not      be deemed to be "filed" for the purpose of Section 18 of the Securities      Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of      that section of the Act but shall be subject to all other provisions of      the Act (however, see the Notes). 

 

> 
**Persons who respond to the collection of information contained in this    form are not required to respond unless the form displays a currently valid    OMB control number.**

CUSIP No. 595073 10 7................................. 

1. Names of Reporting Persons.                     I.R.S. Identification Nos. of above persons (entities only)

G.D. Searle LLC;                                     36-3399885

2. Check the Appropriate Box if a Member of a Group (See Instructions) 

(a) 

(b)      

3. SEC Use Only ........................................................................................  

4. Source of Funds (See Instructions) ......WC..................................................  

5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items    2(d) or 2(e) 

6. Citizenship or Place of Organization - Delaware

Number of Shares Beneficially Owned by Each Reporting Person With:

7. Sole Voting Power.. 600,000............ 

8. Shared Voting Power 

9. Sole Dispositive Power     600,000

10. Shared Dispositive Power ........................................................................................      

11. Aggregate Amount Beneficially Owned by Each Reporting Person. 600,000.............  

12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See    Instructions) ...

13. Percent of Class Represented by Amount in Row (11) 6.1% 

14. Type of Reporting Person (See Instructions) - CO . 

 

 

**UNITED STATES   SECURITIES AND EXCHANGE COMMISSION  Washington, D.C. 20549**

**SCHEDULE 13D  Under the Securities Exchange Act of 1934   (Amendment No. 4)***

**MFIC Corporation**(Name of Issuer) 

**Common Stock, par value $0.01 per share**(Title of Class of Securities) 

**595073 10 7**(CUSIP Number) 

**Margaret M. Foran   Vice President - Corporate Governance and Secretary   Pfizer Inc. 235 East 42nd Street   New York, New York 10017   ( 212)-733-4802**(Name, Address and Telephone Number of Person Authorized to Receive  Notices and Communications) 

**December 31, 2004**(Date of Event which Requires Filing of this Statement) 

> 
Check the appropriate box to designate the rule pursuant to which this          Schedule is filed:

_ Rule 13d-1(b)

x Rule 13d-1(c)

_ Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting          person's initial filing on this form with respect to the subject class          of securities, and for any subsequent amendment containing information          which would alter the disclosures provided in a prior cover page. 

The information required on the remainder of this cover page shall          not be deemed to be "filed" for the purpose of Section 18 of the Securities          Exchange Act of 1934 ("Act") or otherwise subject to the liabilities          of that section of the Act but shall be subject to all other provisions          of the Act (however, see the Notes). 

**Persons who respond to the collection of information contained in        this form are not required to respond unless the form displays a currently        valid OMB control number.**

> 
CUSIP No. 595073 10 7............................... 

15. Names of Reporting Persons.                     I.R.S. Identification Nos. of above persons (entities only)

Pfizer, Inc. ;                                               13-5315170

16. Check the Appropriate Box if a Member of a Group (See Instructions) 

(a) 

(b)     

17. SEC Use Only ........................................................................................  

18. Source of Funds (See Instructions) ......WC..................................................  

19. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items    2(d) or 2(e) 

20. Citizenship or Place of Organization - Delaware

Number of Shares Beneficially Owned by Each Reporting Person With:

21. Sole Voting Power..                   0

22. Shared Voting Power                 

23. Sole Dispositive Power              0      

24. Shared Dispositive Power        

25. Aggregate Amount Beneficially Owned by Each Reporting Person. 600,000.............  

26. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See    Instructions) ...

27. Percent of Class Represented by Amount in Row (11)   6.1 %  

28. Type of Reporting Person (See Instructions) - CO . 

 

This Amendment No. 4 to the Statement on Schedule 13D filed by G.D. Searle  & Co., a Delaware corporation and amended most recently on June 12, 2003,  (the "Schedule 13D") relates to the Common Stock, $.01 par value,  of MFIC Corporation (formerly Microfluidics International Corporation, "Issuer")  and amends the Schedule 13D as follows:

1. Item 5(a) is amended to reflect the percent of class owned by purchaser  of 6.1% based upon the number of shares of Issuer outstanding on December 31,  2004. 

>  

**Signature**

After reasonable inquiry and to the best of my knowledge and belief, I certify  that the information set forth in this statement is true, complete and correct.

February 1, 2005( Date)

 Signature             /s/  Susan Grant                            Susan  Grant, G.D. Searle LLC-Secretary                            (  Name/Title) 

>